Literature DB >> 19176561

Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.

C N Pellegrini1, E Vittinghoff, F Lin, S B Hulley, G M Marcus.   

Abstract

OBJECTIVE: To determine the efficacy of statin treatment in atrial fibrillation (AF) prevention in women.
DESIGN: Cohort study using data obtained in the Heart and Estrogen/Progestin Replacement Study (HERS).
SETTING: Secondary analysis of a multicentre, randomised controlled clinical trial. PATIENTS: 2673 Postmenopausal women with coronary disease. MAIN OUTCOME MEASURES: AF prevalence at baseline and incident AF over a mean follow-up of 4.1 years.
RESULTS: 88 Women with AF were identified: 29 at baseline and 59 during follow-up. Women with AF were significantly less likely to be taking a statin at study enrollment than those without AF (22% vs 37%, p = 0.003). Baseline statin use was associated with a 65% lower odds of having AF at baseline after controlling for age, race, history of myocardial infarction or revascularisation and history of heart failure (odds ratio 0.35, 95% confidence interval (CI) 0.13 to 0.93, p = 0.04). The risk of developing AF during the study among those free from AF at baseline, adjusted for the same covariates, was 55% less for those receiving statin treatment (hazard ratio 0.45, 95% CI 0.26 to 0.78, p = 0.004).
CONCLUSIONS: Statin treatment is associated with a lower prevalence and incidence of AF after adjustment for potential confounders in postmenopausal women with coronary disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176561      PMCID: PMC3170815          DOI: 10.1136/hrt.2008.154054

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  53 in total

1.  Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Authors:  Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

2.  Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker.

Authors:  Guy Amit; Amos Katz; Shikma Bar-On; Harel Gilutz; Avraham Wagshal; Reuven Ilia; Yaakov Henkin
Journal:  Clin Cardiol       Date:  2006-06       Impact factor: 2.882

3.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

4.  Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

Authors:  Ibrahim R Hanna; Brent Heeke; Heather Bush; Lynne Brosius; Diane King-Hageman; Samuel C Dudley; John F Beshai; Jonathan J Langberg
Journal:  Heart Rhythm       Date:  2006-05-09       Impact factor: 6.343

5.  Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein.

Authors:  David Amar; Hao Zhang; Paul M Heerdt; Bernard Park; Martin Fleisher; Howard T Thaler
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

6.  Effect of C-reactive protein reduction on paroxysmal atrial fibrillation.

Authors:  John Dernellis; Maria Panaretou
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

7.  Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.

Authors:  Massimo Chello; Giuseppe Patti; Dario Candura; Stefano Mastrobuoni; Germano Di Sciascio; Felice Agrò; Massimiliano Carassiti; Elvio Covino
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

8.  Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

Authors:  Jeff S Healey; Adrian Baranchuk; Eugene Crystal; Carlos A Morillo; Michael Garfinkle; Salim Yusuf; Stuart J Connolly
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

9.  Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion.

Authors:  Mehmet Ozaydin; Ercan Varol; Suleyman M Aslan; Zehra Kucuktepe; Abdullah Dogan; Mustafa Ozturk; Ahmet Altinbas
Journal:  Am J Cardiol       Date:  2006-03-29       Impact factor: 2.778

10.  Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study.

Authors:  Michael D Hill; David M Kent; Judith Hinchey; Howard Rowley; Alastair M Buchan; Lawrence R Wechsler; Randall T Higashida; Nancy J Fischbein; William P Dillon; Michael Gent; Carolyn M Firszt; Gregory A Schulz; Anthony J Furlan
Journal:  Stroke       Date:  2006-08-03       Impact factor: 7.914

View more
  8 in total

1.  Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.

Authors:  Rosita Zakeri; Alanna M Chamberlain; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2013-08-01       Impact factor: 29.690

2.  Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Brittany Gianetti; Andrew C Zygmunt; Jonathan M Cordeiro; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

Review 3.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

Review 4.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

Review 5.  N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.

Authors:  Javier Mariani; Hernán C Doval; Daniel Nul; Sergio Varini; Hugo Grancelli; Daniel Ferrante; Gianni Tognoni; Alejandro Macchia
Journal:  J Am Heart Assoc       Date:  2013-02-19       Impact factor: 5.501

6.  Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis.

Authors:  Xue Zhou; Jian-lin Du; Jia Yuan; Yun-qing Chen
Journal:  Int J Med Sci       Date:  2013-01-10       Impact factor: 3.738

Review 7.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

Review 8.  Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score.

Authors:  Chen-Ying Hung; Yu-Cheng Hsieh; Jin-Long Huang; Ching-Heng Lin; Tsu-Juey Wu
Journal:  Korean Circ J       Date:  2014-07       Impact factor: 3.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.